Company logo

ENSC - Ensysce Biosciences, Inc.

NASDAQ -> Healthcare -> Biotechnology
La Jolla, United States
Type: Equity

ENSC price evolution
ENSC
(in millions $) 31 Jan 2024 30 Oct 2023 30 Jul 2023 1 May 2023
Current assets
Cash
Short term investments
Net receivables $0.1 $0.1 $0.11 $0.29
Inventory
Total current assets $2.29 $2.8 $5.86 $3.37
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $2.71 $3.2 $6.36 $3.91
Current liabilities
Accounts payable $1.94 $0.9 $1.27 $1.6
Deferred revenue
Short long term debt
Total current liabilities $3.33 $2 $2.52 $3.98
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $3.03 $1.7 $2.24 $3.75
Shareholders' equity
Retained earnings -$121.56 -$118.1 -$115.36 -$113.13
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Current assets
Cash $0.05
Short term investments
Net receivables $0.1 $0.28 $0.44 $0.02
Inventory
Total current assets $2.29 $5.3 $15.66 $0.23
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets $12.63
Total investments
Total assets $2.71 $5.89 $16.42 $12.85
Current liabilities
Accounts payable $1.94 $2.94 $0.3 $0.26
Deferred revenue
Short long term debt
Total current liabilities $3.33 $9.46 $16.48 $0.26
Long term debt $0.14 $4.44 $0.79
Total noncurrent liabilities $13.8
Total debt
Total liabilities $3.03 $9.6 $24.3 $14.06
Shareholders' equity
Retained earnings -$121.56 -$110.93 -$85.85 -$1.21
Other shareholder equity
Total shareholder equity
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Revenue
Total revenue $0.21 $0.6
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $7.26 $5.41
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense -$0.04 -$0.02
Net income
Net income -$7.9 -$0.95
Income (for common shares)
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Revenue
Total revenue $3.53
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $23.4 $1.37 $3.33 $0.96
Operating income -$1.37 -$3.33
Income from continuing operations
EBIT
Income tax expense $0.24 $0.56 $0.55
Interest expense -$0.62 $3.64
Net income
Net income -$29.08 $4.31 -$1.07 $2.12
Income (for common shares)
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing $0 $0
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $6.83 -$0.66 -$0.39 $20.31
Effect of exchange rate
Change in cash and equivalents -$7.76 -$8.53 -$3.82 $12.07
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Net income $4.31 -$1.07
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$0.86 -$1.42
Investing activities
Capital expenditures
Investments
Total cash flows from investing $183.4 $11.85 $0.84
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $20.31 -$183.55 -$11.03 -$0.03
Effect of exchange rate
Change in cash and equivalents $12.07 -$1.01 -$0.6 -$0.43
Fundamentals
Market cap $2.52M
Enterprise value N/A
Shares outstanding 3.15M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 0.69
Quick ratio N/A